Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer. - Li, Guiling; Li, Xiaofan; Yin, Rutie; Feng, Mei; Zuo, Jing; Wei, Shuqing; Kang, Shan; Sun, Hongmei; Li, Xiumin; Wang, Yili; Zhang, Yunyan; Sun, Li; et al. (Gynecologic Oncology, 2024)